Operating
Stock-Based Comp
Eli Lilly Stock-Based Comp increased by 18.3% to $161.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.7%, from $153.70M to $161.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 16.2% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
An increase may signal a strategy to preserve cash or align employee interests with shareholders, but it also results in share dilution.
Detailed definition
Stock-based compensation is a non-cash expense where employees and executives are rewarded with equity or stock options...
Peer comparison
High-growth technology firms often have higher stock-based compensation as a percentage of revenue compared to mature industrial firms.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $91.90M | $90.10M | $75.30M | $101.00M | $92.10M | $85.10M | $92.90M | $131.20M | $161.50M | $215.60M | $120.20M | $159.40M | $211.10M | $133.20M | $141.90M | $153.70M | $185.10M | $151.10M | $136.10M | $161.00M |
| QoQ Change | — | -2.0% | -16.4% | +34.1% | -8.8% | -7.6% | +9.2% | +41.2% | +23.1% | +33.5% | -44.2% | +32.6% | +32.4% | -36.9% | +6.5% | +8.3% | +20.4% | -18.4% | -9.9% | +18.3% |
| YoY Change | — | — | — | — | +0.2% | -5.5% | +23.4% | +29.9% | +75.4% | +153.3% | +29.4% | +21.5% | +30.7% | -38.2% | +18.1% | -3.6% | -12.3% | +13.4% | -4.1% | +4.7% |
Range$75.30M – $215.60M
CAGR+12.5%
Avg YoY Growth+21.0%
Median YoY Growth+15.7%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Eli Lilly's stock-based comp?
- Eli Lilly (LLY) reported stock-based comp of $161.00M in Q1 2026.
- How has Eli Lilly's stock-based comp changed year-over-year?
- Eli Lilly's stock-based comp increased by 4.7% year-over-year, from $153.70M to $161.00M.
- What is the long-term trend for Eli Lilly's stock-based comp?
- Over 4 years (2021 to 2025), Eli Lilly's stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $342.80M to $626.00M.
- What does stock-based comp mean?
- The value of company shares given to employees as part of their pay.